Brain-penetrant microtubule-stabilizing compounds as potential therapeutic agents for tauopathies

Author:

Brunden Kurt R.1,Ballatore Carlo12,Lee Virginia M.-Y.1,Smith Amos B.2,Trojanowski John Q.1

Affiliation:

1. Center for Neurodegenerative Disease Research, Institute on Aging and Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, U.S.A.

2. Department of Chemistry, School of Arts and Sciences, University of Pennsylvania, Philadelphia, PA 19104, U.S.A.

Abstract

Neurons within the brains of those with AD (Alzheimer's disease) and related neurodegenerative disorders, collectively termed ‘tauopathies’, contain fibrillar inclusions composed of hyperphosphorylated tau protein. Tau is normally enriched in axons, where it binds and stabilizes MTs (microtubules). Tau hyperphosphorylation and aggregation probably result in reduced MT binding that could affect axonal transport and neuronal function. A possible therapeutic strategy to overcome a loss of tau function in tauopathies is administration of MT-stabilizing agents, such as those used in the treatment of cancer. However, these drugs elicit severe side effects, and most existing MT-stabilizing compounds have poor BBB (blood–brain barrier) permeability, which renders them unsuitable for tauopathy treatment. We identified EpoD (epothilone D) as a brain-penetrant MT-stabilizing agent with preferred pharmacokinetic and pharmacodynamic properties. EpoD was evaluated for its ability to compensate for tau loss-of-function in an established Tg (transgenic) mouse model, using both preventative and interventional dosing paradigms. EpoD at doses much lower than previously used in human cancer patients caused improved axonal MT density and decreased axonal dystrophy in the tau Tg mice, leading to an alleviation of cognitive deficits. Moreover, EpoD reduced the extent of tau pathology in aged tau Tg mice. Importantly, no adverse side effects were observed in the EpoD-treated mice. These results suggest that EpoD might be a viable drug candidate for the treatment of AD and related tauopathies.

Publisher

Portland Press Ltd.

Subject

Biochemistry

Reference59 articles.

1. Neurodegenerative tauopathies;Lee;Annu. Rev. Neurosci.,2001

2. Tau-mediated neurodegeneration in Alzheimer's disease and related disorders;Ballatore;Nat. Rev. Neurosci.,2007

3. Physical and chemical properties of purified tau factor and role of tau in microtubule assembly;Cleveland;J. Mol. Biol.,1977

4. Physical properties and cellular localization of tau, a microtubule-associated protein which induces assembly of purified tubulin;Cleveland;J. Cell Biol.,1977

5. Modulation of the dynamic instability of tubulin assembly by the microtubule-associated protein tau;Drechsel;Mol. Biol. Cell,1992

Cited by 37 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3